Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages 418-423

  Tohyama, Junichiro ^a   Billheimer, Jeffrey T ^a   Fuki, Ilia V ^a   Rothblat, George H ^b   Rader, Daniel J ^a   Millar, John S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

ApoA I; Cholesterol efflux; HIV; LDL receptor; NNRTIs; RCT

Indexed keywords

APOLIPOPROTEIN A1; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-HIV AGENTS; APOLIPOPROTEIN A-I; BENZOXAZINES; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; CHOLESTEROL, HDL; DIETARY FATS; FEMALE; HUMANS; LIVER; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEVIRAPINE; RECEPTORS, LDL; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; UP-REGULATION;

EID: 67349213582     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.09.016     Document Type: Article

References (31)

1. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
2. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
3. Mulligan K., Grunfeld C., Tai V.W., et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23 (2000) 35-43
4. Tebas P., Yarasheski K., Henry K., et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 20 (2004) 589-594
5. Clotet B., van der Valk M., Negredo E., and Reiss P. Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 34 Suppl 1 (2003) S79-S84
6. Bonjoch A., Paredes R., Domingo P., et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 22 (2006) 321-329
7. Young J., Weber R., Rickenbach M., et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 10 (2005) 585-591
8. Fisac C., Fumero E., Crespo M., et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 19 (2005) 917-925
9. van Leth F., Phanuphak P., Stroes E., et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1 (2004) e19
10. Negredo E., Ribalta J., Paredes R., et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 16 (2002) 1383-1389
11. van der Valk M., Kastelein J.J., Murphy R.L., et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15 (2001) 2407-2414
12. Wilson P.W., Abbott R.D., and Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 8 (1988) 737-741
13. Cuchel M., and Rader D.J. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 113 (2006) 2548-2555
14. Bachmann K., Patel H., Batayneh Z., et al. PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res 50 (2004) 237-246
15. Zhong S., Sharp D.S., Grove J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996) 2917-2923
16. Sviridov D., Chin-Dusting J., Nestel P., et al. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation 81 (2006) 361-366
17. Zhang Y., Da Silva J.R., Reilly M., Billheimer J.T., Rothblat G.H., and Rader D.J. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 115 (2005) 2870-2874
18. Tanne J.H. Pfizer stops clinical trials of heart drug. BMJ 333 (2006) 1237
19. Zhang Y., Zanotti I., Reilly M.P., Glick J.M., Rothblat G.H., and Rader D.J. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 108 (2003) 661-663
20. Gerdes L.U., Gerdes C., Klausen I.C., and Faergeman O. Generation of analytic plasma lipoprotein profiles using two prepacked superose 6B columns. Clin Chim Acta 205 (1992) 1-9
21. Moore R.E., Navab M., Millar J.S., et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 97 (2005) 763-771
22. Batta A.K., Salen G., Batta P., Tint G.S., Alberts D.S., and Earnest D.L. Simultaneous quantitation of fatty acids, sterols and bile acids in human stool by capillary gas-liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 775 (2002) 153-161
23. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 (1959) 911-917
24. Schaefer E.J. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 75 (2002) 191-212
25. Sankatsing R.R., Wit F.W., Pakker N., et al. Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy. J Infect Dis 196 (2007) 15-22
26. Sankatsing R., Franssen R., Hassink E., et al. Nevirapine increases high density lipoprotein-cholesterol by stimulation of apolipoprotein A-I synthesis. Antivir Ther 12 (2007) L5 [Abstract]
27. Hariparsad N., Nallani S.C., Sane R.S., Buckley D.J., Buckley A.R., and Desai P.B. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and Phenobarbital. J Clin Pharmacol 44 (2004) 1273-1281
28. Faucette S.R., Zhang T.C., Moore R., et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320 (2007) 72-80
29. Jackson J.P., Ferguson S.S., Negishi M., and Goldstein J.A. Phenytoin induction of the cyp2c37 gene is mediated by the constitutive androstane receptor. Drug Metab Dispos 34 (2006) 2003-2010
30. Handschin C., and Meyer U.A. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 433 (2005) 387-396
31. Asztalos B.F., de la Llera-Moya M., Dallal G.E., Horvath K.V., Schaefer E.J., and Rothblat G.H. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. J Lipid Res 46 (2005) 2246-2253